Radius Health (RDUS) Misses Q1 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Radius Health (RDUS) Misses Q1 EPS by 14c

Radius Health Reports First Quarter 2017 Financial and Operating Results

May 1, 2017 6:30 AM EDT

US FDA approves TYMLOS (abaloparatide) on April 28, 2017, first new bone builder in nearly 15 years

US Launch set for May 2017

24-month ACTIVExtend trial has concluded, Radius to report top-line results in 2Q 2017

WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported its financial results for the first quarter ended March 31, 2017, and provided a business update.  As of March... More